- Home
- OTLY vs NGNE Comparison
OTLY vs NGNE Comparison
Compare OTLY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- NGNE
- Stock Information
- Founded
- OTLY 1994
- NGNE 2003
- Country
- OTLY Sweden
- NGNE United States
- Employees
- OTLY N/A
- NGNE N/A
- Industry
- OTLY Packaged Foods
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- NGNE Health Care
- Exchange
- OTLY Nasdaq
- NGNE Nasdaq
- Market Cap
- OTLY 428.6M
- NGNE 352.4M
- IPO Year
- OTLY 2021
- NGNE N/A
- Fundamental
- Price
- OTLY $0.66
- NGNE $23.71
- Analyst Decision
- OTLY Buy
- NGNE Strong Buy
- Analyst Count
- OTLY 3
- NGNE 6
- Target Price
- OTLY $1.27
- NGNE $60.80
- AVG Volume (30 Days)
- OTLY 2.6M
- NGNE 542.4K
- Earning Date
- OTLY 02-13-2025
- NGNE 11-18-2024
- Dividend Yield
- OTLY N/A
- NGNE N/A
- EPS Growth
- OTLY N/A
- NGNE N/A
- EPS
- OTLY N/A
- NGNE N/A
- Revenue
- OTLY $813,471,000.00
- NGNE $925,000.00
- Revenue This Year
- OTLY $7.91
- NGNE N/A
- Revenue Next Year
- OTLY $6.85
- NGNE N/A
- P/E Ratio
- OTLY N/A
- NGNE N/A
- Revenue Growth
- OTLY 5.06
- NGNE N/A
- 52 Week Low
- OTLY $0.60
- NGNE $12.49
- 52 Week High
- OTLY $1.40
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OTLY 41.42
- NGNE 41.02
- Support Level
- OTLY $0.63
- NGNE $22.92
- Resistance Level
- OTLY $0.75
- NGNE $25.35
- Average True Range (ATR)
- OTLY 0.04
- NGNE 1.94
- MACD
- OTLY 0.00
- NGNE 1.07
- Stochastic Oscillator
- OTLY 25.46
- NGNE 49.33
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.